Could targeting the menin–KMT2A axis up front improve outcomes in older adults with NPM1-mutated or KMT2A-rearranged AML? In this episode, we examine new phase I data from Zeidner and colleagues, published in The Journal of Clinical Oncology in June 2025, investigating revumenib in combination with azacitidine and venetoclax for newly diagnosed patients ineligible for intensive therapy.
We explore the shared biological mechanism linking these two subtypes, the rationale for adding menin inhibition to ven/aza, and early results—including high remission rates, MRD nuances, and challenges around myelosuppression and treatment delays.
How do these outcomes compare to VIALE-A? Could molecular MRD clearance inform future consolidation strategies? And where might this triplet fit among the growing field of ven/aza-based combinations?
Episode type: Deep Dive potentially relevant to anyone carrying for acute leukaemia patients or interested in menin inhibitors more generally.
